secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2025-09-03T23:59:59+00:00
Accession:  0001640334-25-001617
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences reports positive interim Phase 2 data for ART27.13 in cancer cachexia; seeks licensing partner
--------------------------------------------------------------------------------

- Interim Phase 2 CAReS: ART27.13 patients gained 6.38% mean body weight vs placebo loss of -5.42% at 12 weeks.
- Lean body mass increased +4.23% in treatment group vs -3.15% loss in placebo at one month.
- Safety: 22% of 32 patients had possibly related adverse events, all mild/moderate except one severe malaise; no drug-related serious AEs.
- Company will not internally fund Phase 3; plans to pursue licensing/partnership for ART27.13 as most value-accretive path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001617/0001640334-25-001617-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001617/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-001617

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer